CB-839 induces reversible dormancy in lung tumor-cells
Azemat Jamshidi-Parsian1, Samir V Jenkins2, Amy Tran3
1Department of Environmental Health Sciences, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, USA; Department of Radiation Oncology, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, USA.
European Journal of Pharmacology
|August 19, 2024
Summary
The glutaminase inhibitor CB-839 selectively reduces lung tumor cell function and survival by temporarily inhibiting glutamine metabolism. This reversible effect suggests CB-839 may induce cancer cell dormancy.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Glutaminase inhibitors are investigated as cancer therapeutics.
- Understanding CB-839's molecular mechanisms in lung cancer is crucial.
Purpose of the Study:
- Elucidate CB-839's effects on lung tumor versus non-tumor cell lines.
- Investigate the molecular mechanisms of CB-839 action.
Main Methods:
- Cell viability assays (NADPH dehydrogenases, ATP, mitochondrial reductase).
- Clonogenic survival assays.
- Glutaminase activity and glutamine consumption assays.
- Cell cycle, apoptosis, necrosis, and trypan blue exclusion assays.
Main Results:
- CB-839 demonstrated tumor-specific inhibition of cellular functions and dose-dependent reduction in clonogenic survival (IC50: 10-90 nM).
- CB-839 reduced glutaminase (GLS1) activity and glutamine consumption in tumor cells, with no effect on non-tumor cells.
- Effects were reversible upon drug removal; efficacy was amplified under hypoxia.
- Minimal impact on cell cycle, apoptosis, or necrosis observed.
Conclusions:
- CB-839 exhibits tumor-specific efficacy through reversible glutamine metabolism inhibition.
- The drug's action suggests induction of cancer cell dormancy, particularly under hypoxic conditions.
